FY2029 EPS Estimates for NovoCure Reduced by HC Wainwright

NovoCure Limited (NASDAQ:NVCR) – Analysts at HC Wainwright dropped their FY2029 earnings per share estimates for shares of NovoCure in a research note issued to investors on Thursday, July 23rd. HC Wainwright analyst E. Bodnar now forecasts that the medical equipment provider will post earnings per share of $1.90 for the year, down from their prior estimate of $1.95. The consensus estimate for NovoCure’s current full-year earnings is ($1.41) per share.

NVCR has been the topic of several other research reports. Wells Fargo & Company upped their price objective on shares of NovoCure from $13.50 to $17.00 and gave the company an “equal weight” rating in a research note on Monday, May 4th. Weiss Ratings raised shares of NovoCure from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 1st. Evercore reiterated an “outperform” rating on shares of NovoCure in a report on Friday, May 1st. JPMorgan Chase & Co. initiated coverage on NovoCure in a report on Monday, July 13th. They set a “neutral” rating and a $17.00 price objective on the stock. Finally, Zacks Research downgraded NovoCure from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 14th. Two investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $21.20.

NovoCure Stock Performance

Shares of NASDAQ NVCR opened at $17.65 on Friday. The company has a market cap of $2.04 billion, a PE ratio of -13.58 and a beta of 0.94. NovoCure has a 12 month low of $9.82 and a 12 month high of $21.45. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.90 and a quick ratio of 2.70. The company has a 50-day simple moving average of $16.64 and a 200-day simple moving average of $14.14.

NovoCure (NASDAQ:NVCR) last announced its earnings results on Thursday, July 23rd. The medical equipment provider reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.20. The firm had revenue of $183.58 million during the quarter, compared to the consensus estimate of $172.44 million. NovoCure had a negative net margin of 21.25% and a negative return on equity of 44.02%. The firm’s revenue for the quarter was up 15.6% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.36) EPS.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in NVCR. Empowered Funds LLC acquired a new position in NovoCure in the fourth quarter valued at $33,000. Kestra Advisory Services LLC acquired a new stake in NovoCure during the fourth quarter worth about $49,000. Larson Financial Group LLC increased its stake in NovoCure by 662.1% during the third quarter. Larson Financial Group LLC now owns 4,100 shares of the medical equipment provider’s stock worth $53,000 after acquiring an additional 3,562 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of NovoCure by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,442 shares of the medical equipment provider’s stock worth $70,000 after purchasing an additional 1,120 shares during the period. Finally, Acadian Asset Management LLC purchased a new position in shares of NovoCure in the 1st quarter worth about $87,000. 84.61% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, Director Timothy J. Scannell sold 2,945 shares of the business’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $15.77, for a total value of $46,442.65. Following the completion of the sale, the director directly owned 14,288 shares in the company, valued at approximately $225,321.76. The trade was a 17.09% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jeryl L. Hilleman sold 2,945 shares of the stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $15.77, for a total transaction of $46,442.65. Following the transaction, the director directly owned 13,861 shares in the company, valued at approximately $218,587.97. This represents a 17.52% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 51,943 shares of company stock valued at $893,171. 5.52% of the stock is currently owned by corporate insiders.

Trending Headlines about NovoCure

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: NovoCure reported Q2 EPS of -$0.13, beating the consensus loss estimate of -$0.33, while revenue came in at $183.6 million versus expectations of $172.4 million. Revenue also rose 15.6% year over year, signaling improving business momentum.
• Positive Sentiment: The company raised its FY2026 revenue guidance to $710 million-$725 million, above the market’s prior expectation of about $704 million, which suggests management sees continued demand strength.
• Positive Sentiment: HC Wainwright increased its price target on NovoCure to $52 from $46 and maintained a Buy rating, reinforcing optimism around the company’s longer-term earnings potential. Article Title
• Neutral Sentiment: Wedbush also raised its price target to $20 from $18, but kept a Neutral rating, indicating improved expectations without a strong bullish call. Article Title
• Neutral Sentiment: Shares also got a lift from optimism around the company’s brain therapy pipeline and possible FDA-related catalysts, which helped push the stock to new highs as investors priced in further upside. Article Title
• Negative Sentiment: HC Wainwright trimmed its FY2029 EPS estimate slightly to $1.90 from $1.95, a small caution on the company’s very long-term earnings outlook.

About NovoCure

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.